CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

regn4461

mAbexperimental

Clinical trial activity

9 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
7
Phase 3
3
Phase 4
0

Earliest trial started Apr 24, 2018 (NCT03530514)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2019

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07220785Phase 3Jan 30, 2026Regeneron
NCT07220772Phase 3Dec 19, 2025Regeneron
NCT07235917Phase 2Dec 17, 2025Regeneron
NCT06548100Phase 3Dec 30, 2024Regeneron
NCT06373146Phase 2Apr 24, 2024Eli Lilly, Regeneron
NCT05088460Phase 2Nov 29, 2021Regeneron
NCT04159415Phase 2Dec 2, 2019Regeneron
NCT03530514Phase 1Apr 24, 2018Regeneron
NCT04710056N/A—Regeneron
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RegeneronFor profit9842018
Eli LillyFor profit1112024
2 organizations
Page 1 / 1